RApport Global Strategic Services

What RApport Global Strategic Services does

RApport Global Strategic Services is a UK-headquartered, international regulatory consultancy founded in 2003 and based in Camberley, United Kingdom. The firm delivers regulatory affairs, pharmacovigilance, quality, and compliance consulting services to pharmaceutical, biotechnology, medical device, and combination product companies, with a particular specialty in European regulatory pathways and the EMA/MHRA frameworks that govern product authorization in Europe. RApport employs between 11 and 50 professionals organized around core service lines including European Regulatory Pathway Solutions, Regulatory Affairs Solutions, Pharmacovigilance & Risk Management, Quality & Compliance, Remediation, and GxP Consulting & Implementation. Engagement scope spans pipeline review, clinical program design, CMC strategy, regulatory meeting support, marketing and labeling, lifecycle maintenance, and ongoing post-marketing safety oversight.

The company's business model is professional-services consulting: engagements are quote-based, contracts are enterprise-level, and revenue is generated through billable hours and project fees rather than through software licensing or platform subscriptions. RApport operates strictly as a human-expert delivery organization with no proprietary software or AI tooling disclosed, and there are no API, SDK, or product platform components in the offering. Distribution is direct-enterprise field sales targeting regulatory, clinical, and quality functions within life sciences innovators; marketing is routed through the parent group's website and the IQ Central thought-leadership resource hub.

Since 2024, RApport has operated as one of six founding consultancies within ELIQUENT Life Sciences, a U.S.-anchored regulatory consulting group formed through the combination of Validant, DataRevive, IDEC, Oriel, RApport, and a sixth peer. RApport contributes the European regulatory pillar to ELIQUENT's integrated platform, which extends the combined entity's coverage across the U.S., Europe, and Asia-Pacific and supports more than 50 country markets. RApport's day-to-day operating status remains active under ELIQUENT ownership; financial performance, headcount changes, and pricing are not separately disclosed at the subsidiary level.

Name

RApport Global Strategic Services

Legal name

RApport Global Strategic Services

Website

https://rapportss.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

RApport Global Strategic Services is a UK-based regulatory consultancy providing European regulatory pathway, pharmacovigilance, quality, and compliance consulting to pharmaceutical, biotechnology, and medical device companies, now operating as the European pillar of ELIQUENT Life Sciences.

Ownership category

akta.pro rank

Product category

Regulatory Affairs Consulting

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industry

Strategy & Corporate Development Consulting (BPAHACAA)

Keywords

• Regulatory affairs consulting
• Pharmacovigilance services
• Quality compliance consulting
• Medical device regulation
• GxP implementation

Headquarters

HQ city

Camberley

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Regulatory Consulting Services: Professional consulting services revenue model providing regulatory affairs, pharmacovigilance, quality and compliance solutions to life sciences companies navigating regulatory approval pathways.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

RApport Global Strategic Services provides regulatory affairs, pharmacovigilance, quality, and compliance consulting services to pharmaceutical, biotechnology, medical device, and combination product companies, with specialized expertise in European regulatory pathways. As part of ELIQUENT Life Sciences, the firm delivers end-to-end support spanning product submissions, lifecycle management, inspectional readiness, and market authorization across the U.S., Europe, and Asia.

Product overview

ELIQUENT Life Sciences, built on the foundation of six global life science consultancies including RApport, delivers comprehensive regulatory affairs, pharmacovigilance, quality, and compliance solutions as an integrated platform. RApport specifically contributes UK-based European regulatory pathway expertise to the ELIQUENT portfolio. The services are organized as full-service consulting offerings including Regulatory Affairs Solutions, Pharmacovigilance & Risk Management Solutions, Quality & Compliance Solutions, Remediation Solutions, and GxP Consulting & Implementation. These solutions support pharmaceutical, biotechnology, medical device, and combination product companies across therapeutic modalities, phase-based pathways, and major global markets (U.S., Europe, and Asia). The company functions as a professional services consulting firm rather than a software product platform.

Differentiator

Problem solved

Functional benefit

Products and services

• European Regulatory Pathway Solutions

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• ELIQUENT Life SciencescoreStrategic or Co-development PartnerRApport is a UK-based international regulatory consultancy and one of six global life science consultancies that formed ELIQUENT Life Sciences. RApport's European expertise extends ELIQUENT's global capabilities, providing clients with an expanded portfolio of solutions for gaining and maintaining authorization for products in the European market.

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• PharmaLex: A global life sciences consultancy offering regulatory affairs, pharmacovigilance, quality, and scientific services. Headquartered in Europe with strong FDA/EMA expertise, making it one of the closest comparables to RApport on both regulatory geography and service breadth.
• ProPharma Group: A global regulatory, compliance, pharmacovigilance, and quality consulting firm serving pharma, biotech, and medical device companies. Mirrors RApport's service taxonomy across regulatory strategy, submissions, PV, and quality, serving a similar enterprise life sciences client base.
• Diamond Pharma Services: UK-based regulatory and pharmacovigilance consultancy serving pharma and biotech companies seeking European market authorization. Comparable to RApport by virtue of shared UK/European specialty, similar size profile, and overlapping regulatory affairs and PV offerings.
• Validant: A full-service life science consulting firm that provides regulatory, compliance, and quality services to pharma, biotech, medical device, and diagnostics manufacturers worldwide. Validant is one of RApport's sister consultancies within ELIQUENT Life Sciences, with directly overlapping service lines and customer segments; comparable in offerings, though U.S.-leaning.
• Arriello: A specialist regulatory affairs and pharmacovigilance consultancy focused on helping pharma and biotech companies enter and maintain products in European markets. Highly comparable niche positioning, with similar boutique scale and European pathway specialization.

Broad incumbents

• ICON plc: Global CRO providing regulatory consulting, clinical development, and post-marketing services to pharma and biotech. Overlaps with RApport on regulatory strategy and submissions support but embedded within a much broader clinical research platform.
• PAREXEL International: Established global CRO with regulatory consulting, biopharmaceutical services, and access/medical affairs capabilities serving pharma and biotech. Comparable at the regulatory consulting level, although delivered as one capability within a full-service clinical platform.
• IQVIA: The largest CRO and life sciences services firm, offering regulatory affairs, pharmacovigilance, and quality consulting alongside its broader clinical and commercial capabilities. Competitor at the high end of regulatory consulting with much broader portfolio and technology-enabled delivery.

Regional players

• Biopharma Excellence (PharmaLex Group): European regulatory and scientific consultancy providing CMC, regulatory affairs, and clinical development services primarily to European biotechs. Comparable niche specialization, focused on the EU regulatory pathway RApport also serves.

Emerging players

• Chameleon Pharma Consultancy: European-focused regulatory affairs and market entry consultancy supporting pharma companies in CE marking, EMA submissions, and country-level authorizations. Smaller and more emerging than RApport but with directly comparable European regulatory pathway expertise.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/RapportGlobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RApport Global Strategic Services